Hey, this is an English text. I want you to translate it into the Tunisian dialect. Please follow these steps:
1. Translate step by step and highlight differences between Tunisian dialect and Modern Standard Arabic.
2. Highlight sections you are confident translating into the Tunisian dialect.
Translate this text into the Tunisian dialect, focusing on capturing the essence of the language nuances:

Zhang X‐G, Zhang T, Li C‐Y, Zhang M‐H, Chen F‐M. CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer. Cancer Med. 2018;7:3763--3772. 10.1002/cam4.1607 Xiao‐Guang Zhang and Tong Zhang are contributed equally to the article. 1. INTRODUCTION {#cam41607-sec-0001} =============== Bladder cancer (BC) is the ninth most common cancer and the thirteenth deadliest worldwide with 81190 newly diagnosed cases and 17240 deaths estimated in USA, 2018.[1](#cam41607-bib-0001){ref-type="ref"} Most of bladder cancers are derived from urothelial cells, and roughly 75% of patients are nonmuscle invasive bladder cancer (NMIBC) and 25% have muscle invasive (MIBC) or metastatic disease.[2](#cam41607-bib-0002){ref-type="ref"} Despite the continuous development of medical techniques, the diagnostics, treatments, and survivals for bladder cancer have been largely unchanged since the 1990s.[3](#cam41607-bib-0003){ref-type="ref"} Although NMIBC patients with a better prognosis than MIBC, and even through tumors can be successfully identified and removed before they become invasive, BC has a high rate of recurrence and progression.[4](#cam41607-bib-0004){ref-type="ref"} Cystoscopies are the gold standard for diagnosis of BC, but they are expensive and uncomfortable.[5](#cam41607-bib-0005){ref-type="ref"} And they sometimes fail to find types of tumor that have not yet become invasive but are aggressive, such as carcinoma in situ.[6](#cam41607-bib-0006){ref-type="ref"} With the limitations of present diagnosis and treatment, researching into cancer genomics, risk markers, and targeted therapies could hold the key to progress against this malignant disease. CD164, also known as endolyn or MGC‐24v, is a member of sialomucin family, which is conversed and encoded by CD164 gene located on human chromosome 6q21.[7](#cam41607-bib-0007){ref-type="ref"}, [8](#cam41607-bib-0008){ref-type="ref"} CD164 was first identified in primitive CD34^+^ hemopoietic progenitor cells and bone marrow stromal cells and has been found to be involved in proliferation, migration, and adhesion of these cells.[9](#cam41607-bib-0009){ref-type="ref"}, [10](#cam41607-bib-0010){ref-type="ref"}, [11](#cam41607-bib-0011){ref-type="ref"} By facilitating the adhesion and migration of human CD34^+^ cells to bone marrow stroma, CD164 was proposed to regulate hematopoiesis.[12](#cam41607-bib-0012){ref-type="ref"} In human cancers, CD164 was reported played roles in many different cancers. For instance, CD164 has been reported for the maintenance and progression of human tumors, such as human glioma,[13](#cam41607-bib-0013){ref-type="ref"} lung cancer,[14](#cam41607-bib-0014){ref-type="ref"} ovarian cancer,[15](#cam41607-bib-0015){ref-type="ref"} and prostate cancer.[16](#cam41607-bib-0016){ref-type="ref"} Besides, some microRNAs such as miR‐124 and miR‐219 were found that could suppress the proliferation, migration, and invasion of tumor cells by targeting CD164.[17](#cam41607-bib-0017){ref-type="ref"}, [18](#cam41607-bib-0018){ref-type="ref"} However, the roles of CD164 in BC have not yet been studied and are still unclear. In this study, we systematically researched the roles of CD164 in BC. The immunohistochemistry was used to investigate the associations between CD164 and clinical outcomes of BC patients. Then, the functions of CD164 in tumor proliferation, migration, and invasion were studied in vivo and in vitro. According to these, we hoped to find an effective marker which may become the potential therapeutic target of BC. 2. MATERIALS AND METHODS {#cam41607-sec-0002} ======================== 2.1. Patients and samples {#cam41607-sec-0003} ------------------------- One hundred and fifteen patients clinically and pathologically diagnosed with urothelial carcinoma of bladder in third central hospital of Tianjin and provincial hospital affiliated to Shandong university were included in our study. Tumor tissues were obtained after the first surgical treatment (TURBt or Cystectomy). The clinical and pathological characters such as